Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Immune Thrombocytopenia
NCT05214391Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2022
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Proportion of subjects with a platelet count >= 30 x 10^9/L and 50x10^9/L at 12 weeks. Started Feb 2022; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05214391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05214391.